Long COVID Incidence Declined Over Course of Pandemic

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on July 23, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, July 23, 2024 -- The cumulative incidence of postacute sequelae of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (PASC) during the first year after infection decreased over the course of the pandemic, according to a study published online July 17 in the New England Journal of Medicine.

Yan Xie, Ph.D., from the Veterans Affairs St. Louis Health Care System, and colleagues assessed whether risk and burden of PASC have changed over the course of the pandemic. Analysis included 441,583 veterans with SARS-CoV-2 infection between March 1, 2020, and Jan. 31, 2022, and 4.7 million noninfected controls.

The researchers found that among unvaccinated persons infected with SARS-CoV-2, the cumulative incidence of PASC during the first year after infection was 10.42 events per 100 persons in the pre-delta era, 9.51 events per 100 persons in the delta era, and 7.76 events per 100 persons in the omicron era. Among vaccinated persons, the cumulative incidence of PASC at one year was 5.34 events per 100 persons during the delta era and 3.50 events per 100 persons during the omicron era. Cumulative incidence of PASC at one year was lower among vaccinated versus unvaccinated persons (difference during the delta era, −4.18 events per 100 persons; difference during the omicron era, −4.26 events per 100 persons). At one year during the omicron era, there were 5.23 fewer PASC events per 100 persons than during the pre-delta and delta eras combined, of which 28.1 percent of the decrease was attributable to era-related effects (changes in the virus and other temporal effects), while 71.9 percent was attributable to vaccines.

"The cumulative incidence of PASC during the first year after SARS-CoV-2 infection decreased over the course of the pandemic, but the risk of PASC remained substantial even among vaccinated persons who had SARS-CoV-2 infection in the omicron era," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-07-24 05:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords